Clinical Trials

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06760637 2026-03-02

FourLight-3

1,020 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06507618 2026-02-24

POWER II

354 enrolled

Breast Neoplasms

NCT07288359 2026-02-23

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Breast Neoplasms

NCT06974929 2025-12-30

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

80 enrolled

Breast Neoplasms

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

20 enrolled

Breast Neoplasms

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

102 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06139107 2025-11-14

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Phase 1 Recruiting

15 enrolled

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

375 enrolled

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT05512364 2025-08-19

TREAT ctDNA

220 enrolled

Breast Neoplasms

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

120 enrolled

Breast Neoplasms

NCT06555068 2025-06-22

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

528 enrolled

Breast Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

5,500 enrolled

Breast Neoplasms

NCT04614194 2025-06-02

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

60 enrolled

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

90 enrolled

Breast Neoplasms

NCT03011684 2025-05-08

TALES

309 enrolled

Breast Neoplasms, Infertility

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

766 enrolled

Breast Neoplasms

NCT06235931 2024-02-01

A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC

Phase NA Recruiting

34 enrolled

Breast Neoplasms

NCT05851014 2023-05-09

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

350 enrolled

Breast Neoplasms

NCT05780567 2023-04-21

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

1,946 enrolled

Breast Neoplasms

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

236 enrolled

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

60 enrolled

Breast Neoplasms

NCT05228951 2022-09-13

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

12 enrolled